000			03173nam a22003615i 4500
001			80087
003			ES-MaUEC
005			20230202102420.0
007			cr nn 008mamaa
008			131004s2014 xxk| s |||| 0|eng d
020			_a9781447154242
024	7		_a10.1007/978-1-4471-5424-2 _2doi
050		4	_aRM300 _b.P437 2014
245	1	0	_aPharmacological Treatment of Acute Coronary Syndromes _cedited by Pablo Avanzas, Peter Clemmensen.
260			_aLondon _bSpringer International Publishing _c2014
300			_a1 recurso en línea (XVI, 245 p.) _b24 ilustraciones, 12 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aCurrent Cardiovascular Therapy
505	0		_aForeword -- Preface -- Anti-ischemic Therapy -- Antiaggregant Therapy: New potent P2Y12 inhibitors -- Anticoagulation Therapy: Heparins and Factor Xa inhibitors -- Secondary prevention in ACS The role of novel oral anticoagulants -- American vs European guidelines -- Critical appraisal -- Triple therapy: Risky but sometimes necessary -- Management of bleeding complications.
520			_aThis book updates clinicians on the most recent data regarding the medical management of patients of acute coronary syndrome (ACS), providing useful information and expert opinion on the large trials, international guidelines, and clinical practice. It reinforces the need for rapid intervention with pharmacologic therapies to treat and prevent coronary thromboembolism, and to prepare the patient for revascularization procedures, especially percutaneous coronary intervention. Pharmacological Treatment of Acute Coronary Syndromes describes conventional treatment â€{u0A6E}cluding anti-ischemic, antiplatelet and anticoagulant therapy â€{u086E}d discusses the clinical use of newer treatment options: the potent new P2Y12 platelet receptor inhibitors with the recently recommended ticagrelor and prasugrel, and new oral anticoagulant agents showing promise for acute management and secondary prevention in ACS. Triple therapy, while not initiated in the acute setting, may impact on future surgical and medical emergencies and their management. Also covered are the various recommendations for each of the antiplatelet and anticoagulant agents in terms of patient selection, pretreatment and timing of therapy, making this book an essential read for a wide range of health professionals.
942			_2lcc _cLE
988			_aEBSPRINGER
650		7	_aFarmacia _2embne _9137891
650	2	7	_aFarmacia _2embne _9137891
700	1		_aAvanzas, Pablo _eeditor literario _947108
700	1		_aClemmensen, Peter _eeditor literario _987974 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4471-5424-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12878406 _b10-10-17 _c11-11-15
998			_am _a_alco _a_vill _b11-11-15 _cm _dz _e- _feng _gxxk _h0
945			_aRM300 .P437 2014 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11558222 _z06-04-17
999			_c80087 _d80087 _x1